肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
4期
298-301
,共4页
马好霞%刘丽娜%李晋生%张芳%杨浩浩
馬好霞%劉麗娜%李晉生%張芳%楊浩浩
마호하%류려나%리진생%장방%양호호
多西他赛%替吉奥%晚期胃癌%临床疗效
多西他賽%替吉奧%晚期胃癌%臨床療效
다서타새%체길오%만기위암%림상료효
Docetaxel%S-1%Advanced gastric cancer%Clinical effect
目的:探讨多西他赛联合替吉奥治疗晚期胃癌的临床效果和安全性。方法选择2010年3月~2011年6月在我院治疗的138例晚期胃癌患者,随机分为两组,对照组接受临床一线治疗(DPF方案),实验组患者给予多西他赛联合替吉奥治疗,观察并比较两组患者的近期疗效及不良反应。结果治疗后,实验组和对照组患者的治疗总有效率分别为58.6%和41.2%,实验组显著高于对照组(P<0.05)。治疗过程中,两组患者的主要不良反应包括脱发、恶心、呕吐、骨髓抑制、肝功能受损等,无心脏及肾脏的不良表现。实验组患者不良反应的发生率明显低于对照组(P<0.05)。结论多西他赛联合替吉奥治疗晚期胃癌的临床效果更好,且毒副反应更少,具有更好的临床应用价值。
目的:探討多西他賽聯閤替吉奧治療晚期胃癌的臨床效果和安全性。方法選擇2010年3月~2011年6月在我院治療的138例晚期胃癌患者,隨機分為兩組,對照組接受臨床一線治療(DPF方案),實驗組患者給予多西他賽聯閤替吉奧治療,觀察併比較兩組患者的近期療效及不良反應。結果治療後,實驗組和對照組患者的治療總有效率分彆為58.6%和41.2%,實驗組顯著高于對照組(P<0.05)。治療過程中,兩組患者的主要不良反應包括脫髮、噁心、嘔吐、骨髓抑製、肝功能受損等,無心髒及腎髒的不良錶現。實驗組患者不良反應的髮生率明顯低于對照組(P<0.05)。結論多西他賽聯閤替吉奧治療晚期胃癌的臨床效果更好,且毒副反應更少,具有更好的臨床應用價值。
목적:탐토다서타새연합체길오치료만기위암적림상효과화안전성。방법선택2010년3월~2011년6월재아원치료적138례만기위암환자,수궤분위량조,대조조접수림상일선치료(DPF방안),실험조환자급여다서타새연합체길오치료,관찰병비교량조환자적근기료효급불량반응。결과치료후,실험조화대조조환자적치료총유효솔분별위58.6%화41.2%,실험조현저고우대조조(P<0.05)。치료과정중,량조환자적주요불량반응포괄탈발、악심、구토、골수억제、간공능수손등,무심장급신장적불량표현。실험조환자불량반응적발생솔명현저우대조조(P<0.05)。결론다서타새연합체길오치료만기위암적림상효과경호,차독부반응경소,구유경호적림상응용개치。
Objective To assess the efficacy and safety of docetaxel plus S-1 in the treatment of advanced gastric cancer. Methods From March 2010 to June 2011, 138 patients with advanced gastric cancer admitted in our hospital were selected and randomly divided into experimental group and control group. The control group was given front-line clinical treatment of DPF, while the experimental group was treated by docetaxel and S-1. The short-term efficacy and incidence of side-effects were ob-served and compared after treatment. Results The effective rate of the experimental group was significantly higher than that of the control group (58.6%vs. 41.2%, P<0.05). The main adverse reactions observed during treatment included hair loss, nausea, vom-iting, myelosuppression and liver function damage, while no adverse symptoms of heart or kidney was observed. The incidence of adverse reactions in experimental group was significantly lower than that in the control group (P<0.05). Conclusion Docetaxel plus S-1 was more effective and safer than the current front-line clinical DPF treatment in the treatment of advanced gastric cancer.